BiotechTube

LNP023 + Eculizumab + Ravulizumab

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Timeline

Jan 25, 2021 → Mar 6, 2023

NCT ID
NCT04558918

About LNP023 + Eculizumab + Ravulizumab

LNP023 + Eculizumab + Ravulizumab is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT04558918. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04558918Phase 3Completed

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51
Humanized anti-Factor Bb monoclonal antibody + PlaceboSanofiPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85